Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China · Delayed Price · Currency is CNY 30.05
+0.65 (2.21%)
Aug 21, 2026, 3:00 PM CST
SHA:688319 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,192 | 10,294 | 4,303 | 6,417 | 5,621 | 14,513 | |
Market Cap Growth | -9.29% | 139.25% | -32.95% | 14.17% | -61.27% | - |
Enterprise Value | 12,480 | 10,482 | 4,422 | 6,267 | 5,420 | 14,115 |
Last Close Price | 30.05 | 25.36 | 10.60 | 15.74 | 13.81 | 35.67 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 462.46 | 207.29 | 365.54 | 211.50 | 134.42 |
Forward PE | - | 187.85 | 98.61 | 60.77 | 38.44 | 59.68 |
PS Ratio | 16.05 | 14.62 | 7.31 | 12.94 | 10.27 | 29.79 |
PB Ratio | 14.02 | 11.39 | 4.61 | 6.90 | 6.30 | 17.18 |
P/TBV Ratio | 14.30 | 11.61 | 4.74 | 7.13 | 6.51 | 17.47 |
P/FCF Ratio | - | 1540.54 | - | - | - | - |
P/OCF Ratio | 222.35 | 97.58 | - | 145.85 | - | 363.16 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 16.43 | 14.89 | 7.51 | 12.63 | 9.90 | 28.97 |
EV/EBITDA Ratio | 101.94 | 158.34 | 87.75 | 204.71 | 135.49 | 120.71 |
EV/EBIT Ratio | 151.49 | 320.25 | 204.54 | 1787.91 | 368.70 | 150.33 |
EV/FCF Ratio | - | 1568.66 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.60 | 0.48 | 0.39 | 0.26 | 0.15 | 0.05 |
Debt / EBITDA Ratio | 4.28 | 6.15 | 6.69 | 6.93 | 3.35 | 0.33 |
Debt / FCF Ratio | - | 64.80 | - | - | - | - |
Net Debt / Equity Ratio | 0.33 | 0.20 | 0.13 | -0.13 | -0.25 | -0.49 |
Net Debt / EBITDA Ratio | 2.41 | 2.78 | 2.38 | -4.07 | -5.63 | -3.56 |
Net Debt / FCF Ratio | -9.85 | 27.51 | -0.55 | 0.99 | 1.00 | 13.99 |
Asset Turnover | 0.39 | 0.37 | 0.34 | 0.32 | 0.41 | 0.53 |
Inventory Turnover | 1.06 | 0.85 | 0.38 | 0.49 | 0.56 | 0.47 |
Quick Ratio | 1.18 | 1.23 | 1.37 | 1.80 | 1.63 | 2.34 |
Current Ratio | 1.29 | 1.35 | 1.53 | 1.96 | 1.78 | 2.56 |
Return on Equity (ROE) | -2.68% | 2.38% | 1.69% | 1.26% | 3.06% | 17.68% |
Return on Assets (ROA) | 2.62% | 1.07% | 0.79% | 0.14% | 0.68% | 6.33% |
Return on Invested Capital (ROIC) | -3.95% | 2.10% | 1.64% | 0.35% | 1.63% | 26.12% |
Return on Capital Employed (ROCE) | 6.50% | 2.50% | 1.80% | 0.30% | 1.50% | 10.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.20% | 0.22% | 0.48% | 0.27% | 0.47% | 0.74% |
FCF Yield | -0.24% | 0.07% | -5.04% | -1.96% | -4.01% | -0.21% |
Dividend Yield | - | - | - | 0.24% | - | - |
Payout Ratio | - | 66.11% | 142.97% | 34.11% | 16.00% | 0.95% |
Buyback Yield / Dilution | -0.18% | -0.01% | 0.01% | -0.07% | -5.22% | -5.61% |
Total Shareholder Return | -0.18% | -0.01% | 0.01% | 0.17% | -5.22% | -5.61% |